Literature DB >> 15684072

Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.

Wenxue Li1, Neva West, Emanuela Colla, Olga Pletnikova, Juan C Troncoso, Laura Marsh, Ted M Dawson, Pekka Jäkälä, Tobias Hartmann, Donald L Price, Michael K Lee.   

Abstract

Abnormal biology of alpha-synuclein (alpha-Syn) is directly implicated in the pathogenesis of Parkinson's disease and other alpha-synucleinopathies. Herein, we demonstrate that C-terminally truncated alpha-Syn (alpha-SynDeltaC), enriched in the pathological alpha-Syn aggregates, is normally generated from full-length alpha-Syn independent of alpha-Syn aggregation in brains and in cultured cells. The accumulation of alpha-SynDeltaC is enhanced in neuronal cells as compared with nonneuronal cells. Significantly, the expression of familial Parkinson's disease-linked mutant alpha-Syn is associated with the enhanced cellular accumulation of alpha-SynDeltaC. Moreover, substoichiometric amounts of alpha-SynDeltaC enhance the in vitro aggregation of the more abundant full-length alpha-Syn. Finally, cases of alpha-synucleinopathy exhibit increases in the total soluble alpha-Syn and a higher proportion of soluble alpha-SynDeltaC, a condition favoring the aggregation of alpha-Syn. Collectively, our results indicate that the biology behind the generation and accumulation of alpha-SynDeltaC is likely to have relevance for the initiation and the progression of alpha-Syn aggregation in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15684072      PMCID: PMC548541          DOI: 10.1073/pnas.0406976102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.

Authors:  J E Galvin; K Uryu; V M Lee; J Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

2.  Lewy body diseases and multiple system atrophy as alpha-synucleinopathies.

Authors:  M Goedert; M G Spillantini
Journal:  Mol Psychiatry       Date:  1998-11       Impact factor: 15.992

3.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

5.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.

Authors:  T Kitada; S Asakawa; N Hattori; H Matsumine; Y Yamamura; S Minoshima; M Yokochi; Y Mizuno; N Shimizu
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

6.  NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation.

Authors:  M Hashimoto; M Yoshimoto; A Sisk; L J Hsu; M Sundsmo; A Kittel; T Saitoh; A Miller; E Masliah
Journal:  Biochem Biophys Res Commun       Date:  1997-08-28       Impact factor: 3.575

7.  Effects of the modification of transfer buffer composition and the renaturation of proteins in gels on the recognition of proteins on Western blots by monoclonal antibodies.

Authors:  S D Dunn
Journal:  Anal Biochem       Date:  1986-08-15       Impact factor: 3.365

8.  The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system.

Authors:  A Iwai; E Masliah; M Yoshimoto; N Ge; L Flanagan; H A de Silva; A Kittel; T Saitoh
Journal:  Neuron       Date:  1995-02       Impact factor: 17.173

9.  Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores.

Authors:  T A Bayer; P Jäkälä; T Hartmann; L Havas; C McLean; J G Culvenor; Q X Li; C L Masters; P Falkai; K Beyreuther
Journal:  Neurosci Lett       Date:  1999-05-14       Impact factor: 3.046

10.  Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.

Authors:  Olga Pletnikova; Neva West; Michael K Lee; Gay L Rudow; Richard L Skolasky; Ted M Dawson; Laura Marsh; Juan C Troncoso
Journal:  Neurobiol Aging       Date:  2004-12-28       Impact factor: 4.673

View more
  193 in total

Review 1.  Dynamic structural flexibility of α-synuclein.

Authors:  Danielle E Mor; Scott E Ugras; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Neurobiol Dis       Date:  2015-12-31       Impact factor: 5.996

Review 2.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

3.  Tau Interacts with the C-Terminal Region of α-Synuclein, Promoting Formation of Toxic Aggregates with Distinct Molecular Conformations.

Authors:  Anvesh K R Dasari; Rakez Kayed; Sungsool Wi; Kwang Hun Lim
Journal:  Biochemistry       Date:  2019-06-07       Impact factor: 3.162

Review 4.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

Review 5.  Membranes as modulators of amyloid protein misfolding and target of toxicity.

Authors:  Anoop Rawat; Ralf Langen; Jobin Varkey
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-04-25       Impact factor: 3.747

6.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

Review 7.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 8.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

9.  Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells.

Authors:  Li-Wen Ko; Hwai-Hwa C Ko; Wen-Lang Lin; Jayanranyan G Kulathingal; Shu-Hui C Yen
Journal:  J Neuropathol Exp Neurol       Date:  2008-11       Impact factor: 3.685

Review 10.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.